Data from Design and Preclinical Evaluation of a Novel B7-H4–Directed Antibody–Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305

Michael Davies,Frances Anne Tosto,Anna D Staniszewska,Yann Wallez,David A Tice,Krista Kinneer,R James Christie,Balakumar Vijayakrishnan,Philipp Wortmann,Mary Mcfarlane,Nadia Luheshi,Nazzareno Dimasi,Puja Sapra,Jixin Wang,Darrin Sabol,Judith Anderton,Philip W Howard,Thais Cailleau,Ian Hutchinson,Kathryn Ball,Steven Novick,Niall J Dickinson,Elisabetta Leo,Jon Chesebrough,Zachary A Cooper,Arthur Lewis,Anton I Rosenbaum ,Yue Huang ,Luke A Masterson ,Noel R Monks ,Mark R Albertella ,Jijun Yuan

doi:10.1158/1078-0432.c.6533087

Abstract

<div>AbstractPurpose:We evaluated the activity of AZD8205, a B7-H4–directed antibody–drug conjugate (ADC) bearing a novel topoisomerase I inhibitor (TOP1i) payload, alone and in combination with the PARP1-selective inhibitor AZD5305, in preclinical models.Experimental Design:IHC and deep-learning–based image analysis algorithms were used to assess prevalence and intratumoral heterogeneity of B7-H4 expression in human tumors. Several TOP1i-ADCs, prepared with Val-Ala or Gly–Gly–Phe–Gly peptide linkers, with or without a PEG8 spacer, were compared in biophysical, in vivo efficacy, and rat toxicology studies. AZD8205 mechanism of action and efficacy studies were conducted in human cancer cell line and patient-derived xenograft (PDX) models.Results:Evaluation of IHC-staining density on a per-cell basis revealed a range of heterogeneous B7-H4 expression across patient tumors. This informed selection of bystander-capable Val-Ala–PEG8–TOP1i payload AZ14170133 and development of AZD8205, which demonstrated improved stability, efficacy, and safety compared with other linker–payload ADCs. In a study of 26 PDX tumors, single administration of 3.5 mg/kg AZD8205 provided a 69% overall response rate, according to modified RECIST criteria, which correlated with homologous recombination repair (HRR) deficiency (HRD) and elevated levels of B7-H4 in HRR-proficient models. Addition of AZD5305 sensitized very low B7-H4–expressing tumors to AZD8205 treatment, independent of HRD status and in models representing clinically relevant mechanisms of PARPi resistance.Conclusions:These data provide evidence for the potential utility of AZD8205 for treatment of B7-H4–expressing tumors and support the rationale for an ongoing phase 1 clinical study (NCT05123482).<a href="https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-22-3640" target="_blank">See related commentary by Pommier and Thomas, p. 991</a></div>

Full Text